Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...

Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...

Biotechnology company Moderna (NASDAQ:MRNA) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell ...

Moderna stock surged Thursday after the Covid vaccine-maker significantly cut its third-quarter costs, and still managed to ...

Moderna Inc became the second U.S company to release data from a large study of its experimental vaccine, saying it was 94.5% effective against COVID-19.

Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand ...

The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical ...

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...

Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients will continue.